Feasibility of an obstetrician-based cord blood collection network for unrelated donor umbilical cord blood banking

Wall, Donna A.; Noffsinger, J. M.; Mueckl, K.A.; Alonso, J.M.F.; Regan, Donna; Johnson, Cory; Weinstein, D; Duarte, L. M.; Winn, Hung N.

doi:10.1002/(sici)1520-6661(199711/12)6:6<320::aid-mfm4>3.0.co;2-q

Cited by 26 publications

(15 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In one study, collection by obstetricians during the third stage of labour was compared with collections by cord blood bank technicians after placental delivery. 9 The mean volume collected during the third stage of labour was 81 ml (n ϭ 293), and after placental delivery was 75 ml (n ϭ 41). In a smaller study of 42 collections, 10 a mean volume of 83 ml (s.d.…”

Section: Collectionmentioning

confidence: 61%

Development of a district Cord Blood Bank: a model for cord blood banking in the National Health Service

Donaldson

Buchanan

Webster

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The Bristol Cord Blood Bank was established as a pilot project within existing health services to establish costeffective recruitment, collection and processing suitable for use in the NHS should cord blood become a routine source of haemopoietic stem cells for transplantation in the UK. An important aim of the project was to evaluate the feasibility of establishing a midwifery-based collection network, thus utilising expertise already in place. Collection was performed on the delivery suite immediately after the placenta was delivered. The clinical experience of the midwife collector/counsellors allowed rapid pre-collection assessment of the condition of the cord and placenta. This prevented collection attempts from diseased or otherwise damaged placentas, leading to conservation of resources by preventing collection of most small volume donations. The bank was established within the National Blood Service, Bristol Centre to achieve Good Manufacturing Practice standards and ensure that processing was subject to the same strin- The Bristol Cord Blood Bank (BCBB) was developed as a pilot research project to optimise recruitment, collection and processing of cord blood donations, with future incorporation of cord blood banking into the NHS in mind. An important aim of the project was to evaluate the feasibility of establishing a midwifery-based collection network, thus utilising expertise already in place within the NHS.

show abstract

Section: Collectionmentioning

confidence: 61%

Development of a district Cord Blood Bank: a model for cord blood banking in the National Health Service

Donaldson

Buchanan

Webster

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…[21][22][23][24]31 Unrelated cord blood banks have been developed in New York, St Louis, Worcester, Milan, Dusseldorf, Barcelona, and other sites. 20,[32][33][34][35][36] Conditioning regimens that have been used include cyclophosphamide/TBI (1375 cGy)/antithymocyte globulin, etoposide/cytosine arabinoside/cyclophosphamide/TBI (1200 cGy), melphalan/TBI (1350 cGy), antithymocyte globulin, and others. 22,37 In our study, using 100 cGy TBI, engraftment with cord blood was not demonstrated.…”

Section: Discussionmentioning

confidence: 99%

Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy

Ballen

Becker

Emmons

et al. 2002

Blood

View full text Add to dashboard Cite

Allogeneic stem cell transplantation is curative for certain cancers, but the high doses of chemotherapy/radiotherapy lead to toxicity. Here, we treat patients with refractory cancer with 100 cGy total body irradiation (TBI) followed by infusion of nonmobilized pheresed allogeneic peripheral blood cells. Twenty-five patients, with a median age of 47 years, with refractory cancers were enrolled. Eighteen patients received sibling and 7 received unrelated cord blood cells. Donor chimerism was assessed at weeks 1, 2, 3, 4, and 8 after transplantation. Seven patients with solid tumors received a sibling transplant and 6 received a cord blood transplant; none achieved donor chimerism, but 1 treated at the higher dose level of 1 ؋ 10 8 CD3 ؉ cells/kg had a transient nodal response. Twelve patients with hematologic malignancies were treated; 1 received a cord blood transplant and 11 received sibling donor cells. Nine of these 11 patients achieved donor chimerism, ranging from 5% to 100%. Four patients had sustained complete remission of their cancers, including one patient with transient 5% donor chimerism. The development of chimerism correlated with hematologic malignancy (P < .001), total previous myelotoxic chemotherapy (P < .001), T-cell dose (P ‫؍‬ .03), and graft-versus-host disease (P ‫؍‬ .01). Tumor response correlated with donor chimerism (P ‫؍‬ .01). Engraftment was achieved in patients with hematologic malignancies who had been heavily pretreated, suggesting the degree of immunosuppression may be a determinant of engraftment. Low-dose TBI and allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. (Blood. 2002; 100:442-450)

show abstract

“…In general, since CB is a peripheral blood product, there is a fairly close correlation between TNC and hematopoietic progenitor in the 'conventional' red cell-and plasma-depleted product. [32][33][34][35] As yet, correlative tools to interpret differences between the TNC reported by different banks have not been developed. Unfortunately, multiple attempts at standardizing CD34 and colony forming unit (CFU) quantitation between the labs have not been successful.…”

Section: Selection Of Unrelated Adult Donor Hsc For Transplantation: mentioning

confidence: 98%

Selection of cord blood unit(s) for transplantation

Wall

Chan

2008

Bone Marrow Transplant

View full text Add to dashboard Cite

Selection of cord blood (CB) units for transplantation involves combining both cell dose and HLA matching as independent yet overlapping variables. Cell dose and cell yield at the time of transplant are critical given that the transplants are being performed with minimal cells for reliable engraftment. In transplants for malignant disorders, the greater allogenicity and lower relapse rate associated with the less well-matched units balance any benefit of better HLA matching on TRM. The only factor that has repeatedly been associated with improved outcome post CB transplant is cell dose. The CB inventories are rapidly increasing in size and the quality of CB units being banked (larger, better characterized) is improving. With this, some of our current limitations in CB availability will soon become moot. Explorations into CB expansion and multiple CB unit transplants are addressing the limited cell doses attainable with a single CB collection. [1][2][3][4] At this point, one must conclude that bigger is better when selecting CB units for transplantation.

show abstract

Feasibility of an obstetrician-based cord blood collection network for unrelated donor umbilical cord blood banking

Cited by 26 publications

References 5 publications

Development of a district Cord Blood Bank: a model for cord blood banking in the National Health Service

Development of a district Cord Blood Bank: a model for cord blood banking in the National Health Service

Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy

Selection of cord blood unit(s) for transplantation

Contact Info

Product

Resources

About